The Role of Bisphosphonates Prior to Denosumab Treatment on Rebound Fractures: A Mini Review

키워드

참고문헌 (42)

1. Cosman F, "Clinician's guide to prevention and treatment of osteoporosis", Osteoporos Int, 25, pp.2359~2381 (2014)[DOI]
2. Hernlund E, "Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA)", Arch Osteoporos, 8, pp.136~ (2013)[DOI]
3. Bone HG, "Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass", J Clin Endocrinol Metab, 96, pp.972~980 (2011)[DOI]
4. Bone HG, "10 years of denosumab treatment in postmenopausal women with osteoporosis : results from the phase 3 randomised FREEDOM trial and open-label extension", Lancet Diabetes Endocrinol, 5, pp.513~523 (2017)[DOI]
5. Anastasilakis AD, "Denosumab discontinuation and the rebound phenomenon : A narrative review", J Clin Med, 10, pp.152~ (2021)[DOI]
6. Miller PD, "A review of the efficacy and safety of denosumab in postmenopausal women with osteoporosis", Ther Adv Musculoskelet Dis, 3, pp.271~282 (2011)[DOI]
7. Lorentzon M, "Treating osteoporosis to prevent fractures : current concepts and future developments", J Intern Med, 285, pp.381~394 (2019)[DOI]
8. Polyzos SA, "Clinical vertebral fractures following denosumab discontinuation", Endocrine, 54, pp.271~272 (2016)[DOI]
9. Niimi R, "Second rebound-associated vertebral fractures after denosumab discontinuation", Arch Osteoporos, 15, pp.7~ (2020)[DOI]
10. Lamy O, "Alendronate after denosumab discontinuation in women previously exposed to bisphosphonates was not effective in preventing the risk of spontaneous multiple vertebral fractures : two case reports", Osteoporos Int, 30, pp.1111~1115 (2019)[DOI]
11. Anastasilakis AD, "Progression of rebound-associated vertebral fractures following denosumab discontinuation despite reinstitution of treatment : Suppressing increased bone turnover may not be enough", J Clin Densitom, 24, pp.338~340 (2021)[DOI]
12. Anastasilakis AD, "Multiple clinical vertebral fractures following denosumab discontinuation", Osteoporos Int, 27, pp.1929~1930 (2016)[DOI]
13. Aubry-Rozier B, "Severe spontaneous vertebral fractures after denosumab discontinuation : three case reports", Osteoporos Int, 27, pp.1923~1925 (2016)[DOI]
14. Tripto-Shkolnik L, "Vertebral fractures following denosumab discontinuation in patients with prolonged exposure to bisphosphonates", Calcif Tissue Int, 103, pp.44~49 (2018)[DOI]
15. Lamy O, "Severe rebound-associated vertebral fractures after denosumab discontinuation : 9 clinical cases report", J Clin Endocrinol Metab, 102, pp.354~358 (2017)[DOI]
16. Anastasilakis AD, "Magnetic resonance imaging has an advantage over conventional spine X-rays in the evaluation of rebound-associated vertebral fractures following denosumab discontinuation", Endocrine, 69, pp.516~518 (2020)[DOI]
17. Anastasilakis AD, "Rebound-associated vertebral fractures may occur in sequential time points following denosumab discontinuation : need for prompt treatment re-initiation", Bone Rep, 12, pp.100267~ (2020)[DOI]
18. De Sousa SMC, "Rebound vertebral and non-vertebral fractures during denosumab interruption in a postmenopausal woman", Clin Endocrinol(Oxf), 90, pp.250~252 (2019)[DOI]
19. Miller PD, "Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial", Bone, 43, pp.222~229 (2008)[DOI]
20. Anastasilakis AD, "Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation : Systematic review and additional cases", J Bone Miner Res, 32, pp.1291~1296 (2017)[DOI]
21. Geissler JR, "American Society of Biomechanics Journal of Biomechanics Award 2013 : cortical bone tissue mechanical quality and biological mechanisms possibly underlying atypical fractures", J Biomech, 48, pp.883~894 (2015)[DOI]
22. Dempster DW, "The contribution of trabecular architecture to cancellous bone quality", J Bone Miner Res, 15, pp.20~23 (2000)[DOI]
23. McNamara LM, "Perforation of cancellous bone trabeculae by damage-stimulated remodelling at resorption pits : a computational analysis", Eur J Morphol, 42, pp.99~109 (2005)[DOI]
24. Raggatt LJ, "Cellular and molecular mechanisms of bone remodeling", J Biol Chem, 285, pp.25103~25108 (2010)[DOI]
25. Cummings SR, "Vertebral fractures after discontinuation of denosumab : A post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension", J Bone Miner Res, 33, pp.190~198 (2018)[DOI]
26. Burckhardt P, "Fractures after denosumab discontinuation : A retrospective study of 797 cases", J Bone Miner Res, 36, pp.1717~1728 (2021)[DOI]
27. Lamy O, "Stopping denosumab", Curr Osteoporos Rep, 17, pp.8~15 (2019)[DOI]
28. Popp AW, "Rebound-associated bone loss after non-renewal of long-term denosumabtreatment offsets 10-year gains at the total hip within 12 months", J Bone Miner Res, 31, pp.S408~ (2016)
29. Koldkjær Sølling AS, "Hypercalcemia after discontinuation of long-term denosumab treatment", Osteoporos Int, 27, pp.2383~2386 (2016)[DOI]
30. Leder BZ, "Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab : The Denosumab and Teriparatide Follow-up study(DATA-Follow-up)", Bone, 98, pp.54~58 (2017)[DOI]
31. Kondo H, "Zoledronic acid sequential therapy could avoid disadvantages due to the discontinuation of less than 3-year denosumab treatment", J Bone Miner Metab, 38, pp.894~902 (2020)[DOI]
32. Everts-Graber J, "A single infusion of zoledronate in postmenopausal women following denosumab discontinuation results in partial conservation of bone mass gains", J Bone Miner Res, 35, pp.1207~1215 (2020)[DOI]
33. Anastasilakis AD, "Comparative effect of zoledronate at 6 versus 18 months following denosumab discontinuation", Calcif Tissue Int, 108, pp.587~594 (2021)[DOI]
34. Laroche M, "Effect of risedronate on bone loss at discontinuation of denosumab", Bone Rep, 13, pp.100290~ (2020)[DOI]
35. Anastasilakis AD, "Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass : Effect on bone mineral density and bone turnover markers", Metabolism, 64, pp.1291~1297 (2015)[DOI]
36. Uebelhart B, "Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates", Osteoporos Int, 28, pp.2701~2705 (2017)[DOI]
37. Anastasilakis AD, "Multiple vertebral fractures following denosumab discontinuation : Are we exaggerating?", Calcif Tissue Int, 103, pp.107~108 (2018)[DOI]
38. Anastasilakis AD, "Denosumab versus zoledronic acid in patients previously treated with zoledronic acid", Osteoporos Int, 26, pp.2521~2527 (2015)[DOI]
39. Aubry-Rozier B, "Can we avoid the loss of bone mineral density one year after denosumab discontinuation? The ReoLaus Bone Project", Ann Rheum Dis, 78, pp.115~ (2019)
40. Tripto-Shkolnik L, "Fracture incidence after denosumab discontinuation : Real-world data from a large healthcare provider", Bone, 130, pp.115150~ (2020)[DOI]
41. Japelj M, "Bone mineral density decline following denosumab discontinuation might not be attenuated with previous bisphosphonate therapy", Endocrine Abstracts, 56, pp.P188~ (2018)
42. Florez H, "Spontaneous vertebral fractures after denosumab discontinuation : A case collection and review of the literature", Semin Arthritis Rheum, 49, pp.197~203 (2019)[DOI]

관련 논문AI추천